FacebookTwitter DHHR | BPH | Text size A A A

Merck acquires rights to potential Ebola vaccine in $50M deal


Philadelphia Business Journal
By John George

Merck & Co Inc. entered into a deal for an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink Genetics Corp.'s investigational Ebola vaccine candidate.

Under the terms of the deal, New Link Genetics of Ames, Iowa, will receive $50 million plus royalties from Merck. Merck gets rights to the vaccine candidate and any follow-on products.

Click here to read the full story.

Privacy, Security and Accessibility | WV.gov | USA.gov | © 2017 State of West Virginia